Bhagwan Dass Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -35.97%
(FY 2022)
- Profit 47.05%
(FY 2022)
- Ebitda -492.78%
(FY 2022)
- Net Worth -12.08%
(FY 2022)
- Total Assets 15.95%
(FY 2022)
About Bhagwan Dass Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rekha Sareen, Namrata Arora, and Prajwal Arora serve as directors at the Company.
- CIN/LLPIN
U24304DL2020PLC360532
- Company No.
360532
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Jan 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bhagwan Dass Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rekha Sareen  | Director | 21-Jan-2020 | Current |
| Namrata Arora | Director | 24-Aug-2024 | Current |
| Prajwal Arora | Director | 21-Jan-2020 | Current |
Financial Performance of Bhagwan Dass Pharmaceutical.
Bhagwan Dass Pharmaceutical Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 35.97% decrease. The company also saw a substantial improvement in profitability, with a 47.05% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bhagwan Dass Pharmaceutical?
Unlock access to Bhagwan Dass Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Petula Pharmaceuticals Private LimitedActive 17 years 7 monthsNamrata Arora and Prajwal Arora are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bhagwan Dass Pharmaceutical?
Unlock and access historical data on people associated with Bhagwan Dass Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bhagwan Dass Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bhagwan Dass Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
